Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 2, 2010

View Archived Issues

Search for novel GPR119 receptor agonists yields AS-1669058

Data show no tolerance, rebound or increased use with zolpidem for middle-of-the-night insomnia

UCB discloses new PI3K inhibitors

IntelGenx and RedHill sign agreement for migraine film product

DTCM-G prolongs allograft survival and prevents transplant vasculopathy in mice

Correlation between SNPs in ALOX12 gene and schizophrenia reported in Korean population

AVERROES trial results for apixaban to reduce stroke in AF patients highlighted

Phase Ia trial of INX-08189 completed in chronic hepatitis C

Hungarian authorities approve phase IIa trial of antimicrobial drug Lytixar

Novel inhibitors of tyrosine kinases claimed by sanofi-aventis

Bayer Schering Pharma identifies new Akt inhibitors

Takeda describes novel TrpV1 antagonists

New PKB inhibitors presented by GlaxoSmithKline

Celator achieves funding for CPX-351 trials in AML

Pfizer to acquire FoldRx and its lead product candidate tafamidis

NIAID awards contract to Emergent for anthrax vaccine development

Cellerant awarded BARDA contract to develop ARS treatment

Biodel changes name of insulin formulation from VIAject to Linjeta

Ono receives exclusive rights in Japan to salirasib

Dynavax to study response to hepatitis B vaccination under NIAID grant

HUYA and Sun Yat-sen University to develop novel drugs in China

Daxas global roll-out begins in Germany

Agensys initiates phase I trial of AGS-16M8F in renal cancer

QRxPharma reports interim data of phase III MoxDuo IR study

Evotec closes agreement to acquire DeveloGen

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...